Vanguard Global Advisers
IMNM icon

Vanguard Global Advisers’s Immunome IMNM Stock Holding History

Vanguard Global Advisers’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
49,084
-1,104
-2% -$23.6K ﹤0.01% 1719
2026
Q1 		$1.1M Buy
+50,188
New +$1.12M ﹤0.01% 1606

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vanguard Global Advisers's IMNM Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Immunome (IMNM) stake by 2.2% in Q2 2026, selling an estimated $23.6K and leaving 49,084 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1719.

Vanguard Global Advisers first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.1M in Q1 2026. 201 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Vanguard Global Advisers held 49,084 shares of Immunome worth $1.04M as of Q2 2026.
  • Vanguard Global Advisers sold 1,104 Immunome shares in Q2 2026, an estimated $23.6K.
  • Immunome made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1719 holding.
  • Vanguard Global Advisers first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Immunome position peaked at $1.1M in Q1 2026.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.